Zacks: Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Given $110.00 Average Target Price by Brokerages
Shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Brokers have set a twelve-month consensus price objective of $110.00 for the company and are expecting that the company will post $1.54 EPS for the current quarter, according to Zacks. Zacks has also given Taro Pharmaceutical Industries an industry rank of 65 out of 255 based on the ratings given to its competitors.
TARO has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $110.00 target price (up previously from $105.00) on shares of Taro Pharmaceutical Industries in a research note on Tuesday, November 5th. Zacks Investment Research cut shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Friday, November 8th. Finally, ValuEngine raised shares of Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd.
Shares of TARO traded down $0.10 during trading on Thursday, reaching $96.05. The company’s stock had a trading volume of 637 shares, compared to its average volume of 118,163. The company has a market cap of $3.73 billion, a price-to-earnings ratio of 13.28 and a beta of 0.52. The company has a fifty day moving average of $82.99 and a two-hundred day moving average of $83.81. Taro Pharmaceutical Industries has a twelve month low of $72.97 and a twelve month high of $109.42.
Taro Pharmaceutical Industries (NYSE:TARO) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.72 by ($0.26). The company had revenue of $160.85 million for the quarter, compared to analyst estimates of $168.60 million. Taro Pharmaceutical Industries had a return on equity of 14.13% and a net margin of 40.43%. On average, analysts anticipate that Taro Pharmaceutical Industries will post 6.45 earnings per share for the current fiscal year.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
See Also: Stochastic Momentum Index (SMI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.